Close Menu

More articles about Immunoassays

The ratio of IL-6 to IL-10 biomarkers might give clinicians insight into how severe the inflammatory response to SARS-CoV-2 could be in certain patients.

Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.

The reissued EUA expands the types of samples that may be used with the Broad Institute's PCR-based SARS-CoV-2 test, which was first authorized in July.

Ortho said its antigen test offers 98.9 percent concordance to real-time PCR tests, making it a viable alternative for mass-scale testing during the pandemic.

The test can be used with the Liaison XL, Liaison XS, and Liaison analyzers. More than 8,000 such systems are installed in laboratories worldwide.

Among its recommendations, the FDA said antigen tests for the coronavirus should have a minimum sensitivity of 80 percent for all sample types submitted.

The firm said that its antibody tests detect the presence or absence COVID-19 antibodies and measure their levels.

FIND said the funds were awarded as part of the Access to COVID-19 (ACT) Accelerator Diagnostics Pillar to accelerate testing to help mitigate the pandemic.

The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.

The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.

The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.

The company said it could produce 3 million antigen tests before the end of this year and between 15 million and 20 million tests per month starting next year.

The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.

The company has plans to launch another SARS-CoV-2 antigen test, as well as an immunoassay to detect Epstein-Barr virus in the fourth quarter.

The Italian diagnostics firm believes its test can ID patients with high viral loads rapidly who need to be treated quickly.

MDx revenues grew 67 percent while centralized and POC solutions revenues were down 13 percent, tissue Dx slid 1 percent and diabetes care declined 10 percent.

The company said its rapid antigen test provides results in 15 minutes and is easy to administer for healthcare professionals using a nasopharyngeal swab.

Genomic Vision said it will distribute a test that detects coronavirus antigens from swabs and another that detects IgG and IgM antibodies to the coronavirus in blood. 

The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.

The test has shown almost 100 percent specificity and 95 percent sensitivity in patients tested 15 days after the onset of symptoms.